World Leader in

Cell Expansion & Rejuvenation


June 4, 2024

ExCellThera Announces International Non-proprietary Name and New Orphan Drug Designation for UM171 Cell Therapy

– UM171 Cell Therapy has been granted an International Nonproprietary Name (INN) of “dorocubicel” on the INN Recommended List issued by the World Health Organization (WHO) – The U.S. Food and Drug Administration (FDA) has granted UM171 Cell Therapy (INN-dorocubicel) an additional orphan drug designation to enhance cell engraftment and immune reconstitution MONTREAL, June 4, […]

Read more

About us

Who we are

ExCellThera is an advanced clinical-stage company specializing in cell expansion and engineering, providing molecules and bioengineering solutions to expand and modify various cell lines for use in innovative single-use curative therapies for patients with hematological malignancies and other diseases.

Learn more